Skip to main content
. 2018 Sep 24;16(2):113–130. doi: 10.1038/s41569-018-0080-2

Fig. 3. Anticoagulation in patients with diabetes mellitus and atrial fibrillation.

Fig. 3

Pooled event rates of the various outcome measures from phase III trials comparing non-vitamin K antagonist oral anticoagulants (blue) versus warfarin (red) for the treatment of patients with diabetes and atrial fibrillation. RR, risk ratio.